Abstract: A system and method for manufacturing engineered human lymphocytes for cell therapies, including isolating targeted cells of interest from apheresis starting material using an acoustic separation device and activating the targeted cells of interest in situ with, in certain aspects, antibody-coated surface in an enclosed vessel. Also, the method includes transfecting the targeted cells of interest with construct-encoded lentiviral vectors, retroviral vectors, adeno-associated vectors or non-viral vectors in the enclosed vessel. The cells of interest may then be transfected with viral or non-viral genetic material using an electroporation device. Transfected cells may then be expanded to a desired dose using an expansion feeding method. Also, the method may include combining the targeted cells of interest with cryoprotectant reagents and buffers to create a final formulation.

Abstract: The present disclosure provides a method for culturing cells in exogenous lactic acid. Certain aspects of the present disclosure include the production of recombinant proteins, such as antibodies and fragments thereof. Certain aspects of the present disclosure also relate to methods of controlling lactic acid production, pH stability and osmolality in cell culture.

Abstract: The present disclosure provides a method for culturing cells in exogenous lactic acid. Certain aspects of the present disclosure include the production of recombinant proteins, such as antibodies and fragments thereof. Certain aspects of the present disclosure also relate to methods of controlling lactic acid production, pH stability and osmolality in cell culture.

Abstract: The present disclosure provides a method for culturing cells in exogenous lactic acid. Certain aspects of the present disclosure include the production of recombinant proteins, such as antibodies and fragments thereof. Certain aspects of the present disclosure also relate to methods of controlling lactic acid production, pH stability and osmolality in cell culture.